Rishi P. Singh
VANCOUVER, British Columbia — RG7716, a bispecific antibody designed for intraocular use, resulted in statistically significant visual acuity gains in patients with treatment-naive diabetic macular edema compared with anti-VEGF monotherapy, according to the results of a study presented here.
“Primary endpoints of both 10-letter and 15-letter gains in visual acuity favored the RG7716 group over the anti-VEGF monotherapy group. In addition, it showed improvements in both achieving a dry retina, as well as the two-step retinopathy score improvements in the study,”
Uncategorized